Empirical Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Empirical Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,265	Closed	-$93K	–	458
2021 Q1	$93K	Hold	11,265	–	–	0.01%	380
2020 Q4	$77K	Hold	11,265	–	–	0.01%	358
2020 Q3	$126K	Hold	11,265	–	–	0.01%	332
2020 Q2	$71K	Buy	+11,265	New	+$43.1K	0.01%	322

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Empirical Wealth Management's SRNE Position: Q2 2021 in Review

Empirical Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 11,265 shares — an estimated $93K sold.

Empirical Wealth Management first reported a position in SRNE in Q2 2020 and held it in 4 quarters. The position peaked at $126K in Q3 2020. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

Empirical Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Empirical Wealth Management sold 11,265 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $93K.
Empirical Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
Empirical Wealth Management's Sorrento Therapeutics, Inc. position peaked at $126K in Q3 2020.
212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Empirical Wealth Management's 13F filing for Q2 2021, filed 12 Aug 2021.